APOE rs670318: Low-Density Lipoprotein and Heart Health
The genetic variant rs670318 is a single nucleotide polymorphism located within the apolipoprotein E (APOE) gene region on chromosome 19. Genome-wide association studies have linked this locus with circulating low-density lipoprotein (LDL) cholesterol concentrations and altered susceptibility to cardiovascular disease. Although statistically robust in population studies, current evidence linking this specific marker directly to clinical outcomes remains categorized as limited.
What each genotype means
Typical LDL cholesterol baseline
You carry two copies of the common C allele at rs670318 near the APOE gene region. In population studies, this genotype is generally associated with typical circulating low-density lipoprotein (LDL) cholesterol levels and baseline cardiovascular risk relative to this single locus. Because lipid regulation is influenced by multiple genes and lifestyle factors, this genetic finding represents only one modest contributor to overall cardiovascular health.
Carried by approximately 50% to 65% of individuals across European and East Asian populations.
Modestly lower LDL cholesterol
You have one copy of the T allele associated with altered lipid profiles in genome-wide association studies. Carriers of this single variant copy tend to show slight statistical reductions in circulating LDL cholesterol compared to non-carriers, which may be associated with a modestly lower relative risk of coronary artery disease. However, overall cardiovascular outcomes depend heavily on overall diet, physical activity, and broader metabolic markers.
Carried by roughly 35% to 45% of people of European and East Asian ancestry.
Lower LDL cholesterol tendency
You have inherited two copies of the T allele at this variant within the APOE locus. In genetic epidemiology studies, having two T alleles is associated with a modest statistical decrease in baseline LDL cholesterol levels and slightly lower population-level cardiovascular disease susceptibility compared to the common CC genotype. This statistical association is modest on an individual level and should be considered alongside comprehensive clinical lipid panel measurements.
Carried by approximately 4% to 9% of individuals of European and East Asian ancestry.
Genomic Context and the APOE Gene Region
The single nucleotide polymorphism rs670318 is located on chromosome 19 in close proximity to the apolipoprotein E (APOE) gene cluster. This genomic neighborhood also encompasses other apolipoprotein genes, including APOC1, APOC4, and APOC2, forming one of the most metabolically active clusters in the human genome. Apolipoprotein E is an essential lipid-binding protein primarily produced by the liver and the brain. Its primary physiological duty is facilitating the clearance of triglyceride-rich lipoprotein remnants, including chylomicrons and very-low-density lipoproteins, from the bloodstream. By acting as a critical high-affinity ligand for low-density lipoprotein (LDL) receptors, APOE directly governs how quickly circulating cholesterol is removed from circulation. Single nucleotide variations occurring throughout this cluster can disrupt transcriptional regulation or alter the clearance rate of atherogenic particles.
Research Findings on LDL Cholesterol and Cardiovascular Risk
In large-scale genome-wide association studies cataloged by resources like the NHGRI-EBI GWAS Catalog, rs670318 has been identified as a significant quantitative trait locus for circulating blood lipid levels, especially LDL cholesterol. The apolipoprotein E locus contributes substantial genetic variance to human plasma LDL cholesterol concentrations. Population analyses indicate that alleles at rs670318 show strong linkage disequilibrium with other regulatory and structural variants across the APOE cluster. While the statistical association between this locus and variations in serum LDL cholesterol is reproducible, direct clinical evidence establishing rs670318 as an independently causal driver of coronary events is classified as limited. It largely serves as a genomic proxy tracking wider haplotype variations within the apolipoprotein cluster.
Population Patterns and Ancestry Considerations
The frequency of alleles at rs670318 exhibits meaningful variation across diverse global ancestries. In European and East Asian cohorts, the minor allele frequency typically ranges between 20% and 30%, making heterozygous and alternative homozygous genotypes quite common in these populations. However, lipid genetics within the APOE cluster can show pronounced heterogeneity when examined across African, admixed Hispanic, and indigenous cohorts. In admixed and underrepresented populations, differing background linkage disequilibrium structures mean that a tag SNP like rs670318 may not carry identical predictive strength for LDL cholesterol. Scientists emphasize that genetic associations discovered primarily in European-centric datasets require dedicated multi-ethnic validation before they can be generalized across all demographic groups.
Clinical Interpretation and Practical Application
Discovering your rs670318 genotype provides an educational glimpse into how genetic factors shape baseline lipid metabolism, but it is not a medical diagnosis. A single polymorphism explains only a small fraction of overall cardiovascular risk, which is heavily influenced by non-genetic factors such as dietary saturated fat, exercise, smoking status, and blood pressure. Furthermore, rs670318 cannot substitute for routine clinical lipid panels, which directly measure actual blood levels of LDL, HDL, and triglycerides. If you are concerned about your cardiovascular risk or are currently taking cholesterol-lowering medications such as statins, you should review your clinical laboratory results and medication dosing with your primary care physician or pharmacist rather than making health decisions based solely on personal genomics.
How common is this variant?
The minor allele frequency for rs670318 is estimated between 0.20 and 0.30 in European and East Asian populations, making both heterozygous and homozygous variant genotypes relatively common across these groups.
Frequently asked questions
Does having the rs670318 variant mean I have high cholesterol?
No. Having this variant simply indicates a statistical predisposition toward altered LDL cholesterol levels in population studies. It does not guarantee high cholesterol, as overall lipid profiles are heavily influenced by diet, physical activity, and broader polygenic factors.
Is rs670318 the same thing as the APOE e4 Alzheimer's allele?
No, rs670318 is a distinct single nucleotide polymorphism located within the broader APOE genomic region. While it may reside near or be inherited alongside other APOE markers, it is primarily studied for its associations with blood lipid traits rather than neurodegenerative disorders.
Can I use my rs670318 result to adjust my statin medication?
No. You should never alter, stop, or initiate prescription cholesterol medications based on a direct-to-consumer genetic test. Any discussions regarding medication effectiveness, lipid targets, or dosing adjustments must be conducted directly with your physician or clinical pharmacist.
What is the best way to monitor my cardiovascular risk if I carry this variant?
The most accurate way to monitor your cardiovascular health is through periodic clinical evaluations with a medical provider. Standard fasting lipid panels directly measure your circulating LDL, HDL, and total cholesterol, providing actionable data far superior to single-gene tests.
Sources & further reading
Educational information only, last refreshed 9/11/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs670318?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in APOE
This variant is located in the APOE/TOMM40 locus, which is a major genetic risk factor for late-onset Alzheimer's disease, with the e4 allele significantly increasing risk in a dose-dependent manner.
This variant has been identified via Genomic Informational Field Theory (GIFT) as having a significant association with Alzheimer's disease neuropathology and end-of-life traits.
Downstream variant in the APOE region associated with lipid metabolism profiles and healthspan indicators.
The APOE gene encodes a protein involved in cholesterol transport, with the ε4 allele being a well-established genetic risk factor for late-onset Alzheimer's disease.
Linked to variations in lipid metabolism and heart disease risk.
A newly annotated variant in the APOE region potentially influencing Alzheimer's disease risk.